Since the inception of Modern Trader, a core editorial theme has centered on the wisdom and power of crowds. Editorial emphasis has focused on companies and projects engaged in the collection and analysis of information.
Saturday, 10 December 2016
Last updated 12 hours ago
Jul 1 2014 | 8:32am ET
Two Paulson & Co. strategies have outdone their peers through the first five months of the year, the firm told clients at its mid-year meeting.
The New York-based hedge fund’s credit opportunities fund is up 6.6% through the end of May, Reuters reports. Firm founder John Paulson said at the June 12 event in London that the portfolio is “fully invested” and designed to continue to earn such returns through next year, “outperforming in a low-yielding environment.”
Paulson also discussed the firm’s merger arbitrage strategy, which is up 3.3% over the same period. He said that merger arbitrage spreads are “becoming attractive,” citing Valeant Pharmaceuticals International’s hostile bid for Allergan Inc. and Mallinckrodt’s deal for Questor Pharma.
The talk came some two weeks before Paulson announced a big stake in Allergan and his support for Valeant’s offer, on which it is working with Pershing Square Capital Management.